The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | IMbark study: imetelstat in R/R triple-negative myelofibrosis
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital, Université de Paris, Paris, France, outlines the results of IMbark (NCT024226086), a Phase II study of imetelstat in relapsed/refractory (R/R) triple-negative (TN) myelofibrosis patients with history of previous Janus kinase inhibitor (JAKi) treatment. Encouraging clinical outcomes and overall survival suggests that treatment with imetelstat may overcome the poor results expected in TN patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Advisory boards: Novartis, BMS, Abbvie, Geron
